Chemed (FRA:CXM) Moat Score: 5/10 (As of Jun. 30, 2026)


FRA:CXM Chemed Corp FRA:CXM
78 GF Score
Price €404.00
GF Value €580.90
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Chemed Moat Score?

Chemed FRA:CXM +2.54% 78 Moat Score is 5 as of Jun. 30, 2026. GuruFocus rates FRA:CXM with a GF Score™ of 78/100 and a GF Value™ of €580.90 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 678 Healthcare Providers & Services companies, Chemed ranks better than 96.02% on this metric.

Chemed has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Chemed has Narrow Moat: Chemed Corp has a solid narrow moat due to its leading position in hospice care and plumbing services. It benefits from economies of scale but faces competition and regulatory challenges that limit its moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Chemed might have Narrow Moat - Solid narrow moat.

Chemed  (FRA:CXM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Chemed Moat Score Related Terms

FRA:CXM vs PACS, LFST, CON: Moat Score Comparison

For the Medical Care Facilities subindustry, Chemed's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemed Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Moat Score distribution charts can be found below:

* The bar in red indicates where Chemed's Moat Score falls into.


FRA:CXM
78GF Score
Chemed Corp FRA:CXM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Chemed (FRA:CXM) has a Moat Score of 5 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Chemed ranks #27 out of 678 companies in the Healthcare Providers & Services industry, placing it in the top 4%.
Is Chemed's Moat Score too high?
Chemed's current Moat Score is 5. Based on the distribution chart, Chemed ranks #27 out of 678 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Chemed has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Moat Score compare to PACS and LFST?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #27 out of 678 companies for Moat Score. This places Chemed in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Chemed's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Significantly Undervalued. The stock's GF Value™ is €580.90, compared to a current price of €404.00 — trading 30.5% below its estimated fair value. The current Moat Score is 5. Chemed's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Moat Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chemed (FRA:CXM) Overvalued in 2026?

Based on GuruFocus' analysis, Chemed stock appears to be undervalued. The current stock price of €404.00 is trading 30.5% below its estimated GF Value™ of €580.90. GuruFocus considers Chemed to be Significantly Undervalued.

Key valuation signals for FRA:CXM:

  • Moat Score: 5
  • GF Value™: €580.90 vs. price of €404.00 (30.5% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chemed Business Description

Other Exchanges CHE:USA
Address 255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
78GF Score

Get the complete analysis for FRA:CXM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€404.00
Price
€580.90
GF Value